{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T19:36:07Z","timestamp":1781811367702,"version":"3.54.5"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.intimp.2025.115338","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T03:44:43Z","timestamp":1755834283000},"page":"115338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Preclinical evaluation of STSA-1002, a novel human and rhesus monkeys cross-reactive monoclonal antibody targeting C5a, in acute respiratory distress syndrome models"],"prefix":"10.1016","volume":"164","author":[{"given":"Yingying","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2025.115338_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-019-0069-0","article-title":"Acute respiratory distress syndrome","volume":"5","author":"Matthay","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"8","key":"10.1016\/j.intimp.2025.115338_bb0010","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2016.0291","article-title":"Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries","volume":"315","author":"Bellani","year":"2016","journal-title":"JAMA"},{"issue":"10300","key":"10.1016\/j.intimp.2025.115338_bb0015","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0140-6736(21)00439-6","article-title":"Acute respiratory distress syndrome","volume":"398","author":"Meyer","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2025.115338_bb0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13054-023-04572-w","article-title":"Management of severe acute respiratory distress syndrome: a primer","volume":"27","author":"Grotberg","year":"2023","journal-title":"Crit. Care (Lond., Engl.)."},{"issue":"5","key":"10.1016\/j.intimp.2025.115338_bb0025","article-title":"The role of C5a in acute lung injury induced by highly pathogenic viral infections","volume":"4","author":"Wang","year":"2015","journal-title":"Emerg. Microbes Infect."},{"issue":"4","key":"10.1016\/j.intimp.2025.115338_bb0030","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1056\/NEJMoa032193","article-title":"Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome","volume":"351","author":"Brower","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115338_bb0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1055\/s-0039-1684049","article-title":"Acute respiratory distress syndrome phenotypes","volume":"40","author":"Reilly","year":"2019","journal-title":"Semin. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115338_bb0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1164\/rccm.202311-2011ST","article-title":"An update on Management of Adult Patients with acute respiratory distress syndrome: an official American Thoracic Society clinical practice guideline","volume":"209","author":"Qadir","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.115338_bb0045","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1378\/chest.06-2100","article-title":"Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial","volume":"131","author":"Meduri","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.intimp.2025.115338_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.173947","article-title":"No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomized clinical trial","volume":"897","author":"Jamaati","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2025.115338_bb0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","article-title":"Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial","volume":"8","author":"Villar","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.115338_bb0060","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccm.2024.08.011","article-title":"Steroids and immunomodulatory therapies for acute respiratory distress syndrome","volume":"45","author":"Millar","year":"2024","journal-title":"Clin. Chest Med."},{"issue":"12","key":"10.1016\/j.intimp.2025.115338_bb0065","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.5858\/arpa.2017-0115-SA","article-title":"Molecular and immune biomarkers in acute respiratory distress syndrome: a perspective from members of the pulmonary pathology society","volume":"141","author":"Capelozzi","year":"2017","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.intimp.2025.115338_bb0070","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.immunol.23.021704.115835","article-title":"Role of C5a in inflammatory responses","volume":"23","author":"Guo","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2025.115338_bb0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.imlet.2019.03.014","article-title":"Differential effects of anaphylatoxin C5a on antigen presenting cells, roles for C5aR1 and C5aR2","volume":"209","author":"Zaal","year":"2019","journal-title":"Immunol. Lett."},{"issue":"6","key":"10.1016\/j.intimp.2025.115338_bb0080","first-page":"1058","article-title":"Complement activation in patients at risk of developing the adult respiratory distress syndrome","volume":"130","author":"Duchateau","year":"1984","journal-title":"Am. Rev. Respir. Dis."},{"issue":"8175","key":"10.1016\/j.intimp.2025.115338_bb0085","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(80)91403-8","article-title":"Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Pathophysiological relevance and possible prognostic value","volume":"1","author":"Hammerschmidt","year":"1980","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.intimp.2025.115338_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/v11010039","article-title":"Complement receptor C5aR1 inhibition reduces pyroptosis in hDPP4-transgenic mice infected with MERS-CoV","volume":"11","author":"Jiang","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2025.115338_bb0095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.intimp.2018.03.029","article-title":"C5a receptor1 inhibition alleviates influenza virus-induced acute lung injury","volume":"59","author":"Song","year":"2018","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115338_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13054-021-03482-z","article-title":"Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil extracellular trap axis in neutrophils from COVID-19 patients","volume":"25","author":"Zhang","year":"2021","journal-title":"Critical Care (London, England)"},{"issue":"6","key":"10.1016\/j.intimp.2025.115338_bb0105","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1172\/JCI112506","article-title":"Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates","volume":"77","author":"Stevens","year":"1986","journal-title":"J. Clin. Invest."},{"issue":"3","key":"10.1016\/j.intimp.2025.115338_bb0110","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0022-4804(89)90055-3","article-title":"Complement levels in septic primates treated with anti-C5a antibodies","volume":"46","author":"Hangen","year":"1989","journal-title":"J. Surg. Res."},{"issue":"3","key":"10.1016\/j.intimp.2025.115338_bb0115","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1124\/jpet.108.141572","article-title":"Identification and characterization of NDT 9513727 [N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a novel, orally bioavailable C5a receptor inverse agonist","volume":"327","author":"Brodbeck","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2025.115338_bb0120","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1097\/CCM.0000000000002950","article-title":"Treatment of Paraquat-induced lung injury with an anti-C5a antibody: potential clinical application","volume":"46","author":"Sun","year":"2018","journal-title":"Crit. Care Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.115338_bb0125","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/cid\/ciu887","article-title":"Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys","volume":"60","author":"Sun","year":"2015","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2025.115338_bb0130","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41392-022-01133-5","article-title":"Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation","volume":"7","author":"Gao","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.intimp.2025.115338_bb0135","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S2213-2600(22)00297-1","article-title":"Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"10","author":"Vlaar","year":"2022","journal-title":"Lancet Respir. Med."},{"issue":"12","key":"10.1016\/j.intimp.2025.115338_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/v13122429","article-title":"Soliris to stop immune-mediated death in COVID-19 (SOLID-C19)-a compassionate-use study of terminal complement blockade in critically ill patients with COVID-19-related adult respiratory distress syndrome","volume":"13","author":"Pitts","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.intimp.2025.115338_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00857","article-title":"Combination of ruxolitinib and eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study","volume":"11","author":"Giudice","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115338_bb0150","article-title":"Hydrocortisone rapidly and significantly reduces the IL-6 level in blood and lungs of patients with COVID-19-related ARDS","volume":"28","author":"Guillon","year":"2024","journal-title":"Crit. Care (Lond., Engl.)."},{"issue":"7","key":"10.1016\/j.intimp.2025.115338_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076142","article-title":"Prospective roles of tumor necrosis factor-alpha (TNF-\u03b1) in COVID-19: prognosis, therapeutic and management","volume":"24","author":"Mohd Zawawi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2025.115338_bb0160","doi-asserted-by":"crossref","DOI":"10.1172\/JCI169500","article-title":"IL-1\u03b2 suppression of VE-cadherin transcription underlies sepsis-induced inflammatory lung injury","volume":"133","author":"Xiong","year":"2023","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2025.115338_bb0165","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fimmu.2020.00207","article-title":"Autophagy protects against developing increased lung permeability and hypoxemia by down regulating Inflammasome activity and IL-1\u03b2 in LPS plus mechanical ventilation-induced acute lung injury","volume":"11","author":"Nosaka","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115338_bb0170","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/s41419-022-04589-z","article-title":"Blocking the human common beta subunit of the GM-CSF, IL-5 and IL-3 receptors markedly reduces hyperinflammation in ARDS models","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.intimp.2025.115338_bb0175","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamasurg.2013.3746","article-title":"Airway pressure release ventilation prevents ventilator-induced lung injury in normal lungs","volume":"148","author":"Emr","year":"2013","journal-title":"JAMA Surg."},{"issue":"6","key":"10.1016\/j.intimp.2025.115338_bb0180","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1172\/JCI112743","article-title":"Protein permeability in the adult respiratory distress syndrome. Loss of size selectivity of the alveolar epithelium","volume":"78","author":"Holter","year":"1986","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2025.115338_bb0185","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1532391","article-title":"Sparstolonin B nano-formulation attenuates LPS-induced lung injury","volume":"16","author":"Meng","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.intimp.2025.115338_bb0190","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1186\/cc966","article-title":"Fluid balance and colloid osmotic pressure in acute respiratory failure: emerging clinical evidence","volume":"4","author":"Martin","year":"2000","journal-title":"Crit. Care (Lond., Engl.)."},{"issue":"5","key":"10.1016\/j.intimp.2025.115338_bb0195","first-page":"L579","article-title":"Higher mini-BAL total protein concentration in early ARDS predicts faster resolution of lung injury measured by more ventilator-free days","volume":"312","author":"Hendrickson","year":"2017","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"issue":"11","key":"10.1016\/j.intimp.2025.115338_bb0205","doi-asserted-by":"crossref","DOI":"10.1097\/CCE.0000000000000577","article-title":"Efficacy and safety of Vilobelimab (IFX-1), a novel monoclonal anti-C5a antibody, in patients with early severe Sepsis or septic shock-a randomized, placebo-controlled, double-blind, multicenter, phase IIa trial (SCIENS study)","volume":"3","author":"Bauer","year":"2021","journal-title":"Critical Care Explorations"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925013293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925013293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T13:49:06Z","timestamp":1772891346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925013293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":40,"alternative-id":["S1567576925013293"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115338","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of STSA-1002, a novel human and rhesus monkeys cross-reactive monoclonal antibody targeting C5a, in acute respiratory distress syndrome models","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115338","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115338"}}